The registry obtains the majority of its data from hospitals. However, an increasing number of cancer cases are diagnosed and treated outside of the hospital setting. Thus, to achieve complete case ascertainment, physicians are required to report to the LTR as well. State law requires physicians to report electronically. Additionally, this requirement supports the criterion to qualify for Stage 2 Meaningful Use (MU2) incentives from the Centers for Medicare and Medicaid Services (CMS).
State law requires physicians to report cancer cases within 2 months of diagnosis. If cases are not submitted in compliance with the law, personnel from the LTR may access the records to screen and abstract the required information. The physician will reimburse the LTR for this service.
Reportable cases are any newly diagnosed in situ or invasive neoplasms, as well as benign and borderline tumors of the brain and central nervous system. As for skin cancers, only melanoma cases (including melanoma in situ) are reportable. Basal cell carcinoma, papillary carcinoma, and squamous cell carcinoma cases are NOT reportable. Information about out-of-state residents diagnosed and/or treated in Louisiana is also reportable. The LTR can require reporting of precursor lesions for special surveillance programs.
Options for reporting to the LTR:
- Directly to the LTR via your EHR system (required for MU2 cancer reporting) read more
- WebPlus– Secure online abstracting software
The below flowchart will help you decide which reporting option will best suit your needs. Please contact email@example.com for more information about reporting electronically.